Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Colorcon
Baxter
Express Scripts
Harvard Business School

Last Updated: March 26, 2023

Dihydroergotamine mesylate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for dihydroergotamine mesylate and what is the scope of freedom to operate?

Dihydroergotamine mesylate is the generic ingredient in five branded drugs marketed by Bausch, Hikma, Hikma Pharms, Padagis Us, Provepharm Sas, Sagent Pharms Inc, Amneal, Cipla, Impel Pharms, and Novartis, and is included in twelve NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dihydroergotamine mesylate has sixty-one patent family members in fifteen countries.

There are six drug master file entries for dihydroergotamine mesylate. Eleven suppliers are listed for this compound.

Summary for dihydroergotamine mesylate
Drug Prices for dihydroergotamine mesylate

See drug prices for dihydroergotamine mesylate

Recent Clinical Trials for dihydroergotamine mesylate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ache Laboratorios Farmaceuticos S.A.Phase 3
Xijing HospitalPhase 2/Phase 3
Satsuma Pharmaceuticals, Inc.Phase 3

See all dihydroergotamine mesylate clinical trials

Pharmacology for dihydroergotamine mesylate
Medical Subject Heading (MeSH) Categories for dihydroergotamine mesylate

US Patents and Regulatory Information for dihydroergotamine mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Impel Pharms TRUDHESA dihydroergotamine mesylate SPRAY, METERED;NASAL 213436-001 Sep 2, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Cipla DIHYDROERGOTAMINE MESYLATE dihydroergotamine mesylate SPRAY, METERED;NASAL 212907-001 May 20, 2020 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Bausch D.H.E. 45 dihydroergotamine mesylate INJECTABLE;INJECTION 005929-001 Approved Prior to Jan 1, 1982 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for dihydroergotamine mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch MIGRANAL dihydroergotamine mesylate SPRAY, METERED;NASAL 020148-001 Dec 8, 1997 See Plans and Pricing See Plans and Pricing
Bausch MIGRANAL dihydroergotamine mesylate SPRAY, METERED;NASAL 020148-001 Dec 8, 1997 See Plans and Pricing See Plans and Pricing
Bausch MIGRANAL dihydroergotamine mesylate SPRAY, METERED;NASAL 020148-001 Dec 8, 1997 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for dihydroergotamine mesylate

Country Patent Number Title Estimated Expiration
European Patent Office 3679971 DISPOSITIF D'ADMINISTRATION DE MÉDICAMENT PAR VOIE NASALE (NASAL DRUG DELIVERY DEVICE) See Plans and Pricing
Russian Federation 2741249 НАКОНЕЧНИКИ ДЛЯ НАЗАЛЬНОЙ ДОСТАВКИ ЛЕКАРСТВЕННЫХ СРЕДСТВ (TIPS FOR NASAL DRUG DELIVERY) See Plans and Pricing
New Zealand 741171 In-line nasal delivery device See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Colorcon
Medtronic
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.